Qlaira rPMS (Regulatory Post Marketing Surveillance) Study in Korea

NCT01797809 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 757

Last updated 2019-04-09

No results posted yet for this study

Summary

The objective of this PMS is to gain information about safety and efficacy in real practice as a regulatory commitment required by KFDA (Korea Food and drug administration)

Conditions

  • Contraception

Interventions

DRUG

EV/DNG (Qlaira, BAY86-5027)

Patients in daily life clinical practice tratment receiving Qlaira according to indication on the label.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-11
Primary Completion
2018-01-16
Completion
2018-05-08

Countries

  • South Korea

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01797809 on ClinicalTrials.gov